Extracellular vesicles (EVs) released by Aspergillus fumigatus play key roles in fungal–host communication. Similar to synthetic nanoparticles, fungal EVs acquire a biomolecular corona composed of a tightly bound “hard” corona layer of fungal proteins and a dynamic “soft” layer of host‐derived molecules adsorbed upon contact with biological fluids. Although the corona is thought to modulate EV identity and immunological outcomes, its role in fungal EV–immune cell interactions remains poorly defined. Here, we investigated how corona removal and reconstitution alter the biophysical properties and immunomodulatory function of A. fumigatus EVs. Corona removal reduced EV‐associated protein content and impaired EV‐macrophage interaction, whereas serum exposure promoted secondary corona formation and markedly increased EV association with AMJ2‐C11 macrophages. Native and serum‐coated EVs induced robust secretion of both pro‐inflammatory (IL‐1β, IL‐6, TNF‐α, IFN‐γ) and anti‐inflammatory (IL‐4, IL‐10) cytokines, whereas stripped EVs elicited a markedly attenuated response. At the transcriptional level, serum‐coated EVs upregulated genes involved in innate recognition and signalling pathways ( Tlr2 , Tlr4 , Dectin1 , DC‐Sign and Nf‐κb) as well as macrophage activation programs ( Nos2 , Arg1 , Chi3l3 , Retnla and Tgfb1 ). These findings establish the biomolecular corona as a key determinant of fungal EV immunomodulatory activity. Beyond advancing our understanding of fungal EV biology, this work highlights corona engineering as a potential strategy to reprogram EV–host interactions, with implications for antifungal therapeutic development.
Fungal infections remain a major global health challenge, underscoring the need to better understand host–pathogen interactions. Extracellular vesicles (EVs) released by fungal pathogens are emerging as key modulators of immune responses. Here, we investigated how EVs from Candida albicans and Aspergillus fumigatus influence macrophage activation, focusing on the integration of pattern recognition receptors (PRRs) and cytosolic sensing pathways. EVs were characterized by nanoparticle tracking analysis, zeta potential, and cryo-electron microscopy. Human THP-1-derived macrophages were stimulated with fungal EVs, and cytokine production, gene expression, and signaling pathway activation were assessed by ELISA, RT-qPCR, and Western blotting. C. albicans EVs induced a strong pro-inflammatory response, with increased production of IL-1β, IL-6, TNF, IL-8, and IFN-β after 24 h. In contrast, A. fumigatus EVs elicited a more limited response, characterized by IL-4 production and minimal pro-inflammatory cytokine induction. Both EV populations modulated PRR expression and activated the cGAS–STING–IRF3 axis; however, C. albicans EVs promoted coordinated activation of TLR4, TLR9, and Dectin-1–CARD9 signaling, whereas A. fumigatus EVs downregulated CARD9 and dampened inflammation. These findings demonstrate that fungal EVs differentially shape macrophage responses through species-specific integration of immune sensing pathways.
Non-Saccharomyces yeasts are emerging as promising new probiotics with a beneficial effect equal to or greater than the reference probiotic yeast, Saccharomyces boulardii. Candida intermedia, a non-albicans species not considered a common human pathogen, previously demonstrated probiotic potential. In this work, our objective was to evaluate the immunomodulatory effects of C. intermedia ORQ001 in mice vaccinated with inactivated SARS-CoV-2, seeking further evidence of its probiotic activity. Murine macrophages were stimulated with C. intermedia, followed by mRNA transcription analysis via qPCR. Mice were supplemented with C. intermedia prior to SARS-CoV-2 vaccination. Antibody production was assessed by ELISA, and fecal microbiomes were analyzed using next-generation sequencing. C. intermedia significantly increased Il4 and Il13 expression while decreasing Stat3 in macrophages. Splenocytes from supplemented mice exhibited elevated transcription levels of Tnf, Ifng, Il4, Bcl6, and Stat3 after exposure to stimulatory molecules. These mice showed increased levels of anti-SARS-CoV-2 IgG and sIgA isotypes, along with higher abundances of Bacteroides spp. and Clostridium spp. in their gut microbiome. In conclusion, C. intermedia supplementation modulated the expression of key immune-related genes and enhanced humoral responses in mice. Furthermore, its influence on gastrointestinal microbiota suggests a synergistic effect on vaccine immunogenicity. These findings support the potential of C. intermedia as a novel probiotic candidate with immunomodulatory properties applicable to vaccine adjuvanticity.